Restructuring Groups 2020

How are restructuring groups doing currently? I heard that PJT, LAZ, etc. are even turning down mandates but what about other EB/MM groups like Guggenheim, HL, Rothschild, Jefferies, Centerview, etc.? Which groups are best set up to increase their market positioning during this crisis?

76 Comments
 

The thing to understand about restructuring is that the space is actually very small. In a sense it is like the big 4 accounting firms; if you are a large public company/creditor to them, there is an extremely high likelihood that in the event of a bankruptcy, etc. it is going to be one of PJT, Moelis, Houlihan, or Lazard working on it (plus perhaps Rothschild).

These groups aren't that big either. PJT has 14 restructuring partners, Moelis has 15 MDs, Houlihan has 45 MDs (as a size comparison PJT has ~45 advisory MDs, Moelis has ~100 advisory MDs, and Houlihan has ~120 M&A MDs). As you can imagine all of these restructuring franchises are doing well right now, but you also have to consider that it can take up to 12-18months in some drawn out restructuring cases before the fees are actually realized (though there is a sizeable retainer fee in most structures, at least sizeable compared to M&A). So wouldn't necessarily expect massive Q2/Q3 performances from these firms.

Couldn't find the 2019 data publicly available but it largely looks similar to 2018, which you can download the Reuters report here: https://thesource.refinitiv.com/thesource/getfile/index/025800ef-e1a5-4…

Beyond those names you'll see Evercore, PWP, Greenhill, pick up a handful but not near the levels of the others. Look at the deal value and volume in that report, they are significantly smaller.

 
"Associate 1 in IB - Gen" It's pretty easy to search recent deals in 2019/20 and see that EVR picks up more than just a handful.

They had 12 completed in the US in 2019, that's less than half of what PJT/Moelis/HL each did (at a smaller value per deal as well, except for HL which takes on more MM stuff at times). In 2018 they had 9 completed in the US (again less than half or even a third of the other major players).

Not saying they are a lesser shop by any means but they historically have not had the same size franchise as the others. Of course they will pick up more now but so will everyone else, probably reasonably in proportion to the above.

 

moelis has been doing a bit worse recently, with evr picking up the slack and pwp growing as well

 
Controversial
"Quaneaser" The thing to understand about restructuring is that the space is actually very small. In a sense it is like the big 4 accounting firms; if you are a large public company/creditor to them, there is an extremely high likelihood that in the event of a bankruptcy, etc. it is going to be one of PJT, Moelis, Houlihan, or Lazard working on it (plus perhaps Rothschild).

These groups aren't that big either. PJT has 14 restructuring partners, Moelis has 15 MDs, Houlihan has 45 MDs (as a size comparison PJT has ~45 advisory MDs, Moelis has ~100 advisory MDs, and Houlihan has ~120 M&A MDs). As you can imagine all of these restructuring franchises are doing well right now, but you also have to consider that it can take up to 12-18months in some drawn out restructuring cases before the fees are actually realized (though there is a sizeable retainer fee in most structures, at least sizeable compared to M&A). So wouldn't necessarily expect massive Q2/Q3 performances from these firms.

Couldn't find the 2019 data publicly available but it largely looks similar to 2018, which you can download the Reuters report here: https://thesource.refinitiv.com/thesource/getfile/index/025800ef-e1a5-4…

Beyond those names you'll see Evercore, PWP, Greenhill, pick up a handful but not near the levels of the others. Look at the deal value and volume in that report, they are significantly smaller.

From a distressed buy side perspective, disagree with this. If there is a “top tier” Moelis doesn’t belong in it. Lazard / PJT are top for debtor, HL for creditor. Otherwise Moelis, Evercore, PWP, Centerview, Rothschild, Greenhill, Ducera, Guggenheim pretty interchangeable and comes down to specific circumstances (industry, MD, fund relationships, etc). But yes, in any large restructuring with multiple constituents pretty much every one of the above will have a role somewhere.

 

Having lost so much of their senior talent, Rothschild is nowhere near where they used to be three years ago.

 

Any thoughts on PwC's Business Restructuring Unit? Been approached twice for roles there but not entirely sure where that sits in the heirarchy of desirable places to work at PwC/Restructuring in general. (PwC sits higher than I would've guessed in the league table...)

 

how would you rank these restructuring groups in terms of exit opps? Sorry to be that guy, but following what the above posters are saying, is there a huge discrepancy in opps if you're not in PJT/Laz/HL?

 

Ducera and Houlihan both having a really good year in terms of deal flow/revenue

 

Got a seat at the fulcrum of the Frontier table, going up against PJT/EVR with HL, obviously retained for a reason

 

Head of RX sits there, quality and quantity of work out of the two offices are relatively the same and exits seem solid

 

Deserunt nemo asperiores molestias. Animi et dolores asperiores. Adipisci hic voluptatem in qui ipsum velit.

In doloribus fuga et nesciunt porro totam culpa. Quam reiciendis quia necessitatibus sed fugiat ipsum. Commodi reprehenderit voluptate illo nobis consequuntur saepe corporis.

Alias nemo et officia repellat. Numquam reprehenderit facere possimus ut veritatis pariatur minima. Ut animi itaque quod praesentium quia. Autem illum natus non repellat. Qui qui officiis ab occaecati. Voluptas odit reiciendis quas labore facere commodi. Dolorem quae culpa incidunt reprehenderit.

Aut dolor vero labore consectetur aut. Necessitatibus dolor nobis quasi et aliquam cupiditate.

 

Doloremque est labore suscipit harum quos. Facere omnis repellat mollitia enim perspiciatis. Reprehenderit quidem eum nesciunt enim sunt. Odio provident autem saepe quia amet autem vel. Error explicabo quas rerum qui unde. Quia qui et voluptatum eius recusandae.

Enim officia quia veritatis nam est facilis. In porro soluta excepturi sequi aspernatur consequuntur dolorem.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.8%
  • Morgan Stanley 07 97.2%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.7%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.2%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (81) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”